Addressing genetic tumor heterogeneity through computationally predictive combination therapy.
about
Evolutionary determinants of cancerDeciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicineTumour heterogeneity and the evolution of polyclonal drug resistanceInvadopodia in contextPrimary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategiesPredictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer.Systems biology approaches for advancing the discovery of effective drug combinationsIdentifying and quantifying heterogeneity in high content analysis: application of heterogeneity indices to drug discoveryConceptualizing cancer drugs as classifiersThe challenges of tumor genetic diversity.Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling.Modeling Tumor Clonal Evolution for Drug Combinations DesignPolyclonal rabbit anti-human ovarian cancer globulins inhibit tumor growth through apoptosis involving the caspase signaling.Intratumor heterogeneity alters most effective drugs in designed combinations.A streamlined search technology for identification of synergistic drug combinations.Current and emerging therapies for bone metastatic castration-resistant prostate cancer.A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine.Differential selective pressure alters rate of drug resistance acquisition in heterogeneous tumor populations.Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution.A metric and workflow for quality control in the analysis of heterogeneity in phenotypic profiles and screensNovel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution.Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer.Gene expression profiling for targeted cancer treatment.Clinical management of breast cancer heterogeneity.Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products.A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress.Looking beyond the cancer cell for effective drug combinations.Computational models for predicting drug responses in cancer research.Exploiting receptor tyrosine kinase co-activation for cancer therapy.Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer.Intratumor heterogeneity, variability and plasticity: questioning the current concepts in classification and treatment of hepatocellular carcinoma.Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low ToxicityClinical actionability enhanced through deep targeted sequencing of solid tumorsCombinatorial nanotherapeutics: rewiring, then killing, cancer cells.DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity.Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials.Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance
P2860
Q26801710-259A2F23-E022-4B56-B931-2D65DC6C5F5CQ26825186-D84D7818-346D-4DD1-847A-9BE33E8335C8Q26866803-CE07C3C5-8581-45EB-985F-A25DB8912B9EQ27013793-D96AD326-AE17-4BF2-AB23-9146A2276D0FQ27015224-865F7178-6911-404A-ACEC-7F8AC45180F1Q27331671-9DE527DD-7629-49BF-8A80-A2DFB392671DQ27702922-421B7276-3D87-41B0-866E-6940607AD464Q28540918-E0E90F6F-8967-4F1D-A75E-D8A6FD61BFC3Q28543160-7ACE8E45-C1B7-4E38-ADF0-0BC71A501DEBQ30241056-D2094A64-1853-4F95-A1DD-A0860A4CEBCEQ33589156-276E58F0-147F-4260-9E00-50B3CF684BF2Q33590430-0A49AA5A-407E-4730-8BA4-8803C444D08CQ33612686-34DB4418-421A-42C6-92DE-909AEC5BF2E5Q33972115-F75D3393-A893-43F8-9DFD-BE5F4E0C018CQ36101810-DCC97D4D-7A05-4F67-8B50-41A11878CF5CQ36358303-6217FCDB-2C67-4A52-B782-6805516C783EQ37029832-F9B47C10-D4FE-44F9-8C7C-0970D9F6F874Q37397222-A66F46F6-DF9F-436D-88C7-79BF5DA0A8DDQ37495481-6550E0D9-5A3D-442D-A37F-44325CEAA6C0Q37545380-0784D287-C3FC-44D5-9E4A-0541A06C0FBDQ37695228-258F3A2F-9367-4691-BEF5-DE09176C1042Q38218129-FCC191FF-1E59-4B3D-9DB1-8335681FAB9FQ38259249-D01A2A6C-D4CB-44D3-9D77-2C52B286C844Q38431284-803DBC0B-A93D-483D-AAFF-46A3592D6E15Q38510631-EDBD94FE-04E1-4EE5-8B52-3FF85C08D8D9Q38713515-747BEFAF-8EDD-431D-82CC-F09F2E9A2486Q38728970-308D251E-6259-4A61-97FE-854EF34E6716Q38904995-24A49718-4323-4371-8E45-781AB840AE9DQ38906990-348A6F3D-D7E2-4ED1-A481-BBA73218F850Q39288360-07B93A5E-DFEE-4821-9980-6B1421552323Q39965472-A4562A0D-CCD3-4B77-B223-48A55525ACD5Q41132341-9A18DC62-D769-4357-825E-B62D87459387Q41519437-E920F520-9955-4D3C-9B50-45C1C40363CBQ46641923-1B6B793F-BC26-4458-A6B2-69CBEE47D24CQ52719529-4E1EACA5-8678-4590-BDAC-D30BBAF4AFF9Q55103799-F2662917-E60F-41B6-A886-44793C08A3A1Q58802587-540F50F0-D8F6-4F6F-8C5C-549C5D8DA515
P2860
Addressing genetic tumor heterogeneity through computationally predictive combination therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Addressing genetic tumor heter ...... redictive combination therapy.
@en
Addressing genetic tumor heter ...... redictive combination therapy.
@nl
type
label
Addressing genetic tumor heter ...... redictive combination therapy.
@en
Addressing genetic tumor heter ...... redictive combination therapy.
@nl
prefLabel
Addressing genetic tumor heter ...... redictive combination therapy.
@en
Addressing genetic tumor heter ...... redictive combination therapy.
@nl
P2093
P2860
P1433
P1476
Addressing genetic tumor heter ...... redictive combination therapy.
@en
P2093
Boyang Zhao
Justin R Pritchard
Michael T Hemann
P2860
P304
P356
10.1158/2159-8290.CD-13-0465
P577
2013-12-06T00:00:00Z